Hyperuricemia and chronic heart failure: is there any connection?


Cite item

Full Text

Abstract

Prevalence, pathogenetic and prognostic significance of hypeuricemia in chronic heart failure is discussed. Efficacy of drug treatment of hyperuricemia in chronic heart failure is discussed

About the authors

S R Gilyarevskiy

References

  1. Gwadry-Sridhar F.H., Flintoft V., Lee D.S., et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004;164:2315-2320.
  2. Kenchaiah S., Narula J., Vasan R.S. Risk factors for heart failure. Med Clin North Am. 2004;88:1145-1172.
  3. Krishnan E. Hyperuricemia and Incident Heart Failure. Circ Heart Fail 2009;2:556-562.
  4. Strasak A., Ruttmann E., Brant L., et al. Ulmer H. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008;54:273-284.
  5. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16:3553-3562.
  6. Johnson R.J., Rodriguez-Iturbe B., et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431-440.
  7. Kanellis J., Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42.
  8. Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-865.
  9. Coutinho Tde A., Turner S.T., Peyser P.A., et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007;20:83-89.
  10. Ruggiero C., Cherubini A., Ble A., et al. Uric acid and inflammatory markers. Eur Heart J 2006;27:1174-1181.
  11. Leyva F., Anker S.D., Godsland I.F., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-1822.
  12. Olexa P., Olexova M., Gonsorcik J., et al. Uric acid-a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr 2002;114:211-215.
  13. Annemans L., Spaepen E., Gaskin M., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-966.
  14. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-145.
  15. Krishnan E., Kwoh C.K., Schumacher H.R., Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303.
  16. Sundstrom J., Sullivan L., D'Agostino R.B., et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33.
  17. Avram Z., Krishnan E. Hyperuricaemia-where nephrology meets rheumatology. Rheumatology (Oxford) 2008;47:960-964.
  18. Baker J.F., Krishnan E., Chen L., Schumacher H.R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-826.
  19. Tomita M., Mizuno S., Yamanaka H., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-409.
  20. Kanbay M., Ozkara A., Selcoki Y., et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227--1233.
  21. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. J Am Med Assoc 2008;300:924-932.
  22. Samuelsson O., Wilhelmsen L., Pennert K., Berglund G. Angina pectoris, intermittent claudication and congestive heart failure in middle-aged male hypertensives. Development and predictive factors during long-term antihypertensive care. The Primary Preventive Trial, Goteborg, Sweden. Acta Med Scand 1987;221:23-32.
  23. Doehner W., Schoene N., Rauchhaus M., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624.
  24. Struthers A.D., Donnan P.T., Lindsay P., et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-234.
  25. Cingolani H.E., Plastino J.A., Escudero E.M., et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006;12:491-498.
  26. Cleland J.G., Coletta A.P., Clark A.L. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 2006;8:764-766.
  27. Alcaino H., Greig D., Chiong M., et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008;10:646-651.
  28. Ogino K., Kato M., Furuse Y., et al. Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure. A Double-Blind Placebo-Controlled Crossover Preliminary Study. Circ Heart Fail 2010;3:73-81.
  29. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997.
  30. Cappola T.P., Kass D.A., Nelson G.S., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-2411.
  31. Jankowska E.A., Ponikowska B., Majda J., et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007;115:151-155.
  32. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthineoxidase and extracellular superoxide dismutase. Circulation 2002;106:3073-3078.
  33. Doehner W., von Haehling S., Anker S.D. Uric acid in CHF: marker or player in a metabolic disease? Int J Cardiol 2007;115:156-158.
  34. Gavin A.D., Struthers A.D. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005;91:749-753.
  35. Hare J.M., Mangal B., Brown J., et al. Impact of Oxypurinol in Patients With Symptomatic Heart Failure Results of the OPT-CHF Study. J Am Coll Cardiol 2008;51:2301-2309.
  36. Landmesser U., Spiekermann S., Preuss C., et al. Angiotensin II induces endothelial xanthine oxidase activation. Role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007;27:943-948.
  37. Doerries C., Grote K., Hilfiker-Kleiner D., et al. Critical role of NAD(P)H oxidase subunit p47(phox) for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007;100:894-903.
  38. Doehner W., Anker S.D. Uric acid in chronic heart failure. Semin Nephrol 2005;25:61-66.
  39. Reyes A.J. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail 2005;7:461-467.
  40. Hoieggen A., Alderman M.H., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041- 1049.
  41. Watanabe S., Kang D.H., Feng L., et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355-360.
  42. Minhas K.M., Saraiva R.M., Schuleri K.H., et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006;98:271-279.
  43. Mellin V., Isabelle M., Oudot A., et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005;26:1544-1550.
  44. Saavedra W.F., Paolocci N., St John M.E., et al. Imbalance betweenxanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002;90:297-304.
  45. Naumova A.V., Chako V.P., Ouwerkerk R., et al. Xanthine oxidase inhibitors improve energetics and function following infarction in the failing mouse heart. Am J Physiol Heart Circ Physiol 2006;290:H837-843.
  46. Spiekermann S., Landmesser U., Dikalov S., et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease-relation to endothelium-dependent vasodilation. Circulation 2003;107:1383-1389.
  47. Baldus S., Koster R., Chumley P., et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Rad Biol Med 2005;139:1184-1190.
  48. Farquharson C.A., Butler R., Hill A., et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-226.
  49. Stull L.B., Leppo M.K., Szweda L., et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004;95:1005-1011.
  50. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction-a new action for an old drug? Circulation 2004;110:2175-2179.
  51. George J., Carr E., Davies J., et al. High dose allopurinol improves endothelial dysfunction by profoundly reducing vascular oxidative stress and not by uric acid lowering. Circulation 2006;114:2508-2516.
  52. Becker M.A., Schumacher H.R. Jr, Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.
  53. Schlesinger N. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Curr Rheumatol Rep 2010;12:130-134.
  54. Xu X., Hu X., Lu Z., et al. Xanthine Oxidase Inhibition with Febuxostat Attenuates Systolic Overload-induced Left Ventricular Hypertrophy and Dysfunction in Mice. J Card Fail 2008;14:746-753.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies